Paris, France, December 9, 2019, 7.30 am CET – The National Eye Hospital (CHNO) of the Quinze-Vingts in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal... read more

Lund, Sweden, 08:45 CET, December 9 2019 BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone injuries, today announced the publication of the Level I clinical study CERTiFy in the highly ranked Journal of Bone and Joint Surgery. The authors concluded that CERAMENT® BVF w... read more

STOCKHOLM — December 8, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at the ASH Annual Meeting 2019. In the data presented, melflufen and dexamethasone demonstrated positive efficacy in combi... read more

Stockholm – December 6, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will host a webcast on Tuesday, December 10th, 2019, at 13:00 (CET) to provide an update regarding  the data presented  December 7-8 at the American Society Hematology (ASH) Annual Mee... read more

Oslo, Norway, 4 December 2019 Nordic Nanovector ASA (OSE: NANO) announces that new data from preclinical studies investigating the effect of Betalutin® (177Lu-lilotomab satetraxetan) on non-Hodgkin's lymphoma (NHL) cell lines will be presented in a poster at the 61st American Society of H... read more